Compassionate Use of Avacopan in Difficult-to-Treat Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
- PMID: 35257076
- PMCID: PMC8897689
- DOI: 10.1016/j.ekir.2021.11.036
Compassionate Use of Avacopan in Difficult-to-Treat Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Figures

References
-
- Inacio P. FDA Approves Tavneos as Add-on Therapy for Severe MPA, GPA. ANCA Vasculitis News. https://ancavasculitisnews.com/2021/10/11/fda-approves-tavneos-avacopan-... Published October 11, 2021. Accessed October 29, 2021.
-
- Wexler M. EU Committee Recommends Approval of Tavneos for Severe, Active AAV. ANCA Vasculitis News. https://ancavasculitisnews.com/2021/11/15/eu-committee-chmp-recommends-a... Published November 15, 2021. Accessed November 19, 2021.
LinkOut - more resources
Full Text Sources